Library Header Image
LSE Research Online LSE Library Services

Pharmaceutical policy reform in the Russian federation

Rudisill, C., Vandoros, Sotiris and Antoun, J. G. (2014) Pharmaceutical policy reform in the Russian federation. Journal of Health Politics, Policy and Law, 39 (3). pp. 691-705. ISSN 0361-6878

Full text not available from this repository.
Identification Number: 10.1215/03616878-2682659


Of Russia's 142 million citizens, fewer than 20 million are enrolled in outpatient drug coverage plans. The current government aims to establish universal health insurance including outpatient medicines. Based on the current political and regulatory environment, this report explores pharmaceutical pricing options for Russia that balance greater access to medicines with achieving government plans of boosting local pharmaceutical production. To match innovative medicine prices with their health benefits, in the long run, we suggest that Russia consider adopting value-based pricing, and in the short term, that it introduce direct price negotiations and price drugs according to reference countries that use health technology assessment. Although generic market shares are high, generic medicine prices are higher than they should be.We propose tenders at the manufacturer level for the pricing of high-selling generics, and free pricing for products with sufficient market competition. These policy recommendations are a jumping-off point for further discussion about how pharmaceutical policy could aid this major economy to achieve its population health and health service goals.

Item Type: Article
Official URL:
Additional Information: © 2014 by Duke University Press
Divisions: Social Policy
LSE Health
Subjects: J Political Science > JA Political science (General)
Date Deposited: 01 Jul 2014 11:53
Last Modified: 20 Jul 2021 01:02
Funders: Eli Lilly for the research that has led to this publication

Actions (login required)

View Item View Item